Schweizer, Michael T.

Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling

Bluemn, E. G., Coleman, I. M., Lucas, J. M., Coleman, R. T., Hernandez-Lopez, S., Tharakan, R., Bianchi-Frias, D., Dumpit, R. F., Kaipainen, A., Corella, A. N., et al. (2017) · Cancer Cell

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 744

Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies

Graham, L. S., Montgomery, B., Cheng, H. H., Yu, E. Y., Nelson, P. S., Pritchard, C., Erickson, S., Alva, A., & Schweizer, M. T. (2020) · PLOS ONE

Prostate Cancer Treatment and ResearchCancer Immunotherapy and Biomarkers

Cited by 114

Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer

Lim, E. A., Schweizer, M. T., Chi, K. N., Aggarwal, R., Agarwal, N., Gulley, J., Attiyeh, E., Greger, J., Wu, S., Jaiprasart, P., et al. (2023) · Clinical Genitourinary Cancer

Prostate Cancer Treatment and ResearchCancer Immunotherapy and Biomarkers

Cited by 62

Durable Response to Immune Checkpoint Blockade in a Platinum-Refractory Patient With Nonseminomatous Germ Cell Tumor

Chi, E. A., & Schweizer, M. T. (2017) · Clinical Genitourinary Cancer

Cancer Immunotherapy and BiomarkersTesticular diseases and treatments

Cited by 37

1804P APEX-01: First-in-human phase I/II study of ARX517 an anti- prostate-specific membrane antigen (PSMA) antibody-drug conjugate (ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Shen, J., Pachynski, R., Nordquist, L. T., Adra, N., Bilen, M. A., Aggarwal, R., Reichert, Z., Schweizer, M., Iravani, A., Aung, S., et al. (2023) · Annals of Oncology

Prostate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and Applications

Cited by 24